180 Life Sciences Corp. (NASDAQ: ATNF or the “Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced Tuesday the successful closing of its transaction with KBL Merger Corp IV. Following the merger, 180 Life Sciences shall survive as a wholly-owned subsidiary of KBLM.
Read the full article: 180 Life Sciences Announces Completion of Transaction with KBLM Merger Corp IV //
Source: https://www.globenewswire.com/news-release/2020/11/10/2124086/0/en/180-Life-Sciences-Announces-Completion-of-Transaction-with-KBLM-Merger-Corp-IV.html